The Comparison Between Intravenous Acetaminophen Versus Oral Ibuprofen in Preterm Newborns With Patent Ductus Arteriosus: A Clinical Trial

Message:
Article Type:
Research/Original Article (دارای رتبه معتبر)
Abstract:
Objectives

Oral ibuprofen has been known as a conventional treatment for closing patent ductus arteriosus(PDA) in preterm newborns. Since the use of it might lead to various side effects, other treatments needed to be evaluated. Therefore in a prospective study, we compared the efficacy and safety of intravenous acetaminophen versus oral ibuprofen for the closure of PDA.                                   

Methods

In this study which was done prospectively and under control, 50 preterm neonates with gestational ages and weights less than 37 weeks old and 2500 grams, respectively, who had PDA, large enough hemodynamically, were included in the study. The patients were divided into two groups: A(intravenous acetaminophen) & B(oral ibuprofen). The two groups were given at most two 3-day courses of the medication(the second course if necessary) and evaluated at the end of each course by echocardiography so as to determine the response to the treatment at each step. The rate of  ductal closure, the need for additional treatment, side effects, complications and the newborn’s clinical status were recorded. 

 Results:

The rate of ductal closure in the both groups after one course of treatment was similar and showed no meaningful significance statistically(P value=0.306). But that of the side effects was much higher in group B with a P value=0.021.

Conclusion

Intravenous Acetaminophen is not only as efficatious as oral Ibuprofen for the treatment

Language:
English
Published:
Acta Medica Iranica, Volume:58 Issue: 12, Dec 2020
Pages:
631 to 636
magiran.com/p2216296  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 1,390,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
In order to view content subscription is required

Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!